Investor.seattlegenetics.com

Clay Siegall is a biotechnology expert who is changing the lives of cancer patients in the world. He is the founder of a company known as Seattle Genetics. The biotechnology company was founded in the year 1998, and it has developed several therapies...

COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab...

The global next-generation antibody therapeutics market was valued at $1,490.0 million in 2014 and it is expected to grow at a CAGR of 20.9% during the period 2015 – 2020. The global next-generation antibody therapeutics market is increasing due to growing...

The Co-Founder of Seattle Genetics, Clay Siegall, was recently added to the Board of Directors at Mirna Therapeutics, a Seattle based biotechnology company. Siegall will remain the CEO and Chairman of the Board at his Seattle Genetics. His position with...

Clay Siegell, Ph.D. is the President, Chairman of the Board and Chief Executive Officer of Seattle Genetics- a company he co-founded in 1998. Dr. Siegall received his Ph.D. in Genetics from the University of George Washington and a B.SC. in Zoology from...